MFSD1 and lung adenocarcinoma: Lung adenocarcinoma patients with high MFSD1 expression had a median overall survival of 150 months, compared with 72.3 months in the low expression cohort (the patient group was split at the median) (Figure 6B), while the prognoses of lung squamous cell carcinoma patients were unaffected by MFSD1 expression (data not shown).